GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (OTCPK:PHYOF) » Definitions » EBITDA Margin %

IXICO (PHYOF) EBITDA Margin % : -4.13% (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is IXICO EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. IXICO's EBITDA for the six months ended in Sep. 2023 was $-0.18 Mil. IXICO's Revenue for the six months ended in Sep. 2023 was $4.29 Mil. Therefore, IXICO's EBITDA margin for the quarter that ended in Sep. 2023 was -4.13%.


IXICO EBITDA Margin % Historical Data

The historical data trend for IXICO's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO EBITDA Margin % Chart

IXICO Annual Data
Trend Sep13 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.33 13.78 18.81 18.01 -10.61

IXICO Semi-Annual Data
Sep13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.50 12.44 22.65 -17.60 -4.13

Competitive Comparison of IXICO's EBITDA Margin %

For the Biotechnology subindustry, IXICO's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IXICO's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where IXICO's EBITDA Margin % falls into.



IXICO EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

IXICO's EBITDA Margin % for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=-0.875/8.249
=-10.61 %

IXICO's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-0.177/4.285
=-4.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IXICO  (OTCPK:PHYOF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


IXICO EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of IXICO's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


IXICO (PHYOF) Business Description

Traded in Other Exchanges
Address
15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (PHYOF) Headlines

No Headlines